Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Beroni Group's Pre-Tax Income for the
six
months ended in Jun. 2024 was A$-0.64 Mil. Beroni Group's Revenue for the
six
months ended in Jun. 2024 was A$0.17 Mil. Therefore, Beroni Group's pretax margin for the quarter that ended in Jun. 2024 was -372.25%.
The historical rank and industry rank for Beroni Group's Pretax Margin % or its related term are showing as below:
XNEC:BTG's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.28 * Ranked among companies with meaningful Pretax Margin % only.
Beroni Group (XNEC:BTG) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Beroni Group Pretax Margin % Related Terms
Beroni Group Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Beroni Group's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XNEC:BTG vs PNXP, CRYM, GCAN: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beroni Group Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beroni Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Beroni Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beroni Group (XNEC:BTG) has a Pretax Margin % of -372.25% as of Jun. 2024. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Beroni Group and its competitors.
Is Beroni Group's Pretax Margin % too high?
Beroni Group's current Pretax Margin % is -372.25%. Overall, Beroni Group has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's Pretax Margin % compare to PNXP and CRYM?
Beroni Group's Pretax Margin % of -372.25% can be compared against companies in the Drug Manufacturers industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Beroni Group and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beroni Group's current Pretax Margin % is -372.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (XNEC:BTG) has a current Pretax Margin % of -372.25%. The current Pretax Margin % is -372.25%. Beroni Group's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Beroni Group (XNEC:BTG), the current Pretax Margin % is -372.25% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
4GF Score
Get the complete analysis for XNEC:BTG
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XNEC:BTG has been successfully added to your 
